WAVE Life Sciences

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Munich,,Bavaria,,Germany,-,March,31,2023:,Wave,Life,Sciences

Biotech

News

Health Care

Movers

Trading Ideas

General

Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.

Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year

Insmed’s Stellar Performance Draws Attention

Initiation

Markets

Analyst Ratings

Morgan Stanley Market Vectors Rupee/USD ETN

INSM

KRUS

MAZE

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Oklo_Powerhouse_3_Datacenter

Mid Cap

$BTC

AMZN

CLSK

IONQ

LBPH

OKLO

WOLF

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences Ltd

Press Releases

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Earnings

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

BGM Group

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Cormedix

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GH Research

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harrow

Indivior

Innoviva

LENZ Therapeutics

Liquidia

Nuvation Bio

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Cantor Fitzgerald

HC Wainwright & Co.

Jefferies

Mizuho

Truist Securities

Comments

WAVE Life Sciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell